Lataa...
Exemestane for Breast Cancer Prevention: A Critical Shift?
The Mammary Prevention 3 (MAP.3) placebo-controlled randomized trial in 4,560 high-risk postmenopausal women showed a 65% reduction in invasive breast cancer with the use of exemestane at 35 months median follow-up. Few differences in adverse events were observed between the arms, suggesting a promi...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3354700/ https://ncbi.nlm.nih.gov/pubmed/22585166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0248 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|